Cyclosporine nephrotoxicity  by Myers, Principal discussant: Bryan D.
Kidney International, Vol. 30 (/986), pp. 964—9 74
NEPHROLOGY FORUM
Cyclosporine nephrotoxicity
Principal discussant: BRYAN D. MYERS
Stanford University School of Medicine, Stanford, California
Case presentation
A 28-year-old man was evaluated at Stanford University Medical
Center 6 years ago and was found to have idiopathic cardiomyopathy.
Over the ensuing 2 years he developed progressively severe cardiac
failure that became increasingly refractory to conventional drug ther-
apy. At age 25, he received a cardiac allograft from an ABO-compatible
cadaveric donor. The surgery was uncomplicated; cardiopulmonary
bypass required 74 minutes. Serum creatinine concentration prior to
surgery was 1.3 mg/dl, and the urine was free of protein. He had no
history of renal disease or hypertension. Cyclosporine and prednisone
were administered postoperatively. The initial dose of cyclosporine, 17
mg/kg/day, was tapered gradually to 5 mg/kg/day when the patient was
discharged on postoperative day 52.
The serum creatinine concentration rose progressively during the
postoperative period, reaching levels that fluctuated between I .7 and
2.6 mg/dl. Significant hypertension necessitated antihypertensive treat-
ment. The following factors were considered as possibly contributing to
the elevated serum creatinine level: (1) treatment with cimetidine, a
known blocker of tubular creatinine secretion [1], (2) a 14-day course of
tobramycin (80 mg every 16 or 24 hours) to treat klebsiella pneumonia,
(3) an episode of acute, reversible cardiac allograft rejection on post-
operative day 27, and (4) a deep-vein thrombosis complicated by a
pulmonary embolus (and presumed low cardiac output) on postopera-
tive day 40, for which he was given anticoagulant medication. im-
munoassayable cyclosporine (iCsA) in serum was measured thrice
weekly; trough levels fluctuated widely over a range of 200 to 700 ng/ml.
The subsequent course has been characterized by chronic azotemia
accompanied by hypertension. As Table 1 shows, serum creatinine
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levels increased from 2.4 mg/dl 12 months after transplantation to 3.5
mg/dl 6 months later, despite low-dose CsA therapy (4,0 to 4.5
mg/kg/day) and serum trough levels of iCsA that were usually below 150
ng/ml.
A renal biopsy revealed focal tubular atrophy and interstitial fibrosis.
Mesangial prominence was evident in some glomeruli, whereas wrin-
kling and collapse of peripheral capillary loops suggestive of ischemia
were present in others. These findings were thought to represent
chronic CsA-associated nephropathy; accordingly, CsA was discontin-
ued and azathioprine was begun. Despite this change in medication,
renal function continued to deteriorate (Table 1). Increasing azotemia
was accompanied by modest urinary protein losses (1 g/24 hours) and
persistent arterial hypertension. By 36 months after transplantation, the
GFR had fallen to a level approaching end-stage renal failure (13
ml/min/l.73 m2); cardiac allograft function was excellent.
Discussion
DR. BRYAN D. MYERS (Acting Head o,f Nephrology Division,
and Pro,fèssor of Medicine, Stanford University, Stan fbrd,
California): Almost a decade has elapsed since the introduction
of cyclosporine A (CsA) into clinical medicine as an im-
munosuppressive agent. Whereas its efficacy as an immune
suppressant is undisputed, particularly in the treatment of
allograft rejection, a serious problem of nephrotoxicity has
emerged. Abundant evidence has now accumulated indicating
that GsA therapy can lead to a wide spectrum of renal damage.
The mechanism by which the drug injures the kidney remains
poorly understood, however. Equally obscure is the preva-
lence, extent, and final outcome of CsA-associated renal injury.
Three main reasons can be cited for our present state of
ignorance. First, attempts to develop a rodent analogue of the
human renal injury, particularly in its chronic form, have been
unsuccessful. Second, the overwhelming clinical experience
with the use of CsA has been in renal transplant recipients.
These patients are particularly unsuited to the clinical investi-
gation of CsA nephrotoxicity because the coexistence of acute
and/or chronic rejection makes CsA-induced derangements in
renal allografi function and structure difficult to isolate. Third,
the techniques used for evaluating renal function in CsA-treated
patients are relatively unsophisticated, With rare exceptions,
the detection, evaluation, and monitoring of the renal injury
caused by this agent have been limited to determinations of the
serum creatinine level. The resulting information has been too
crude to shed much light on the evolution, pathophysiology,
and pathogenesis of CsA-associated renal injury. Nevertheless,
because most of the information about CsA-related renal injury
has been gathered in renal transplant recipients, I will review
the three major syndromes that occur in such patients. To
circumvent the ubiquitous possibility of rejection in the trans-
planted kidney, however, I will illustrate my analysis, wherever
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Table 1. Clinical and laboratory features of a cardiac allograft recipient
Months after transplant
0 3 6 12 18 24 30 36
Serum creatinine (mg/do 1.3 2.0 1.8 2.4 3.5 3.7 4.3 4.5
GFR (ml/min/1.73 ,n2)a — — — 46 28 22 — 13
Renal plasma flow' (ml/min/l.73 m) — — — 178 194 210 — 95
Cardiac index (liter/min/1.O m2) -. — — 2.8 — 4.0 — 4.9
CsA dose (mg/kg/day) — 4.7 5.8 4.2 4.5 0 0 0
iCsA trough level (ng/mI) — 69 295 74 116 — — —
Azathioprine (mg/day) — 0 0 0 0 200 200 75
Prednisone (mg/day) — 14 19 9 9 14 12 12
a Inulin clearance.
b Clearance divided by extraction ratio of PAH.
possible, with our own observations of CsA-associated nephrop-
athy in heart transplant patients with previously healthy native
kidneys.
Transient acute renal failure
Clinical features. The administration of CsA is complicated
in most renal transplant recipients by one or more episodes of
acute renal insufficiency [1—3]. Such episodes most commonly
occur in the weeks or months following the initiation of therapy
but also can occur after years of CsA therapy [4]. The decline in
renal function that attends this acute injury is usually brief and
rapidly reversible after the daily CsA dose is reduced [4, 5].
This acute renal injury is by no means unique to the trans-
planted kidney, as evidenced by numerous reports of reversible
azotemia in CsA-treated patients with previously healthy native
kidneys [6, 7]. Figure 1 illustrates one such patient. In this
instance, the CsA-treated individual was a heart transplant
recipient with healthy native kidneys and excellent, early
cardiac allograft function. The patient had a stable creatinine
clearance of 70 mi/mm by the end of the first posttransplant
week, followed by two abrupt decrements of creatinine clear-
ance with reciprocal changes in the serum creatinine level. The
first episode, on postoperative days 7 and 8, was associated
with a modest increase in the trough level of immunoassayable
CsA in serum and was followed by prompt but partial recovery.
The second decrement in creatinine clearance, on posttrans-
plant days 13 and 14, was associated with a rise in the trough
level of CsA into a range regarded as toxic for this assay (500 to
700 nglrnl) [8]. A reduction of the CsA dose was followed by a
return of trough levels to the target therapeutic range (50 to 200
nglml). The ensuing week witnessed a linear increase in creat-
mine clearance to pre-injury levels. On day 8, during the nadir
of the initial fall in creatinine clearance, inulin clearance was
low (37 mllmin), the patient had isosthenuria, and fractional
sodium excretion was only 1.0%, notwithstanding concurrent
diuretic therapy.
Because acute renal allograft rejection also is characterized
by an abrupt fall in GFR, impaired urinary concentrating
ability, and sodium retention, acute CsA-induced renal injury is
difficult to distinguish from acute rejection in renal transplant
recipients. The diagnosis usually is made retrospectively, when
the acute renal injury resolves in the wake of a reduction in
cyclosporine dosage [4, 5]. Frequently, improving renal func-
tion in this setting is accompanied by a decline in trough CsA
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Fig. 1. Course of transient, acute renal inju,y induced by CsA in a heart
transplant recipient as reflected by changes in the clearance and serum
level of creatinine (lower panel). Corresponding trough levels of im-
munoasssayab e CsA in serum appear in he upper panel. Evaluation of
the evolving (1 ) and resolving stages ( 2 ) of the injury reveal respec-
tive inulin clearances of 37 and 45 mI/mm. U/P osmolality ratios were
1.0 and 1.5, and fractional sodium excretion was 1.0% at both times (not
shown).
levels from initially elevated levels. Blood level monitoring has
proved unreliable, however, and both false-positive (high
trough CsA levels with normal renal function) and false-neg-
ative results (reversible azoteniia with trough levels of CsA well
within the therapeutic range) are well documented [9].
Histopathologic features. The difficulty of recognizing acute
rejection in CsA-treated renal-transplant recipients has
prompted many transplant centers to perform needle biopsies of
the kidney when acute azotemia becomes manifest [3, 5, 10].
Under these circumstances, CsA-induced acute renal injury is
frequently identified by an absence of the histopathologic
stigmata of rejection [10, 11]. Although acute CsA nephrotox-
icity is thus diagnosed largely by exclusion, it has been linked
with a number of morphologic alterations of tubular cells. These
include giant mitochondria and prominent vacuole formation in
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proximal tubular cells [11]. Each of these morphologic findings
is, however, nonspecific and of limited diagnostic utility. More
promising perhaps is the work of von Willebrand and Häyry.
Using indirect immunofluorescence and immunoperoxidase
techniques to study needle aspirates of the renal cortex, they
found that during CsA ncphrotoxicity, CsA is bound by
vacuolated tubular cells [5]. The technique of needle aspiration
is less traumatic than is renal biopsy, but, as a diagnostic test
for acute CsA nephrotoxicity, it appears to yield an unaccept-
ably high rate of false-positive and false-negative results. The
finding of intracapillary glomerular thrombosis appears to be
more specific for acute CsA-induced renal injury [7, 12, 131.
Although reminiscent of the thrombotic microangiopathy that is
associated with the hemolytic-uremic syndrome, evidence of
accelerated erythrocyte destruction has rarely been demon-
strated during the course of acute, reversible renal injury in
CsA-treated patients 1121. Moreover, intracapillary glomerular
thrombi during the course of CsA therapy have been found in
only a minority of patients and underestimate the prevalence of
episodes of reversible impairment of renal function [12]. Ac-
cordingly, the precise relationship of this microvascular abnor-
mality to the common form of acute CsA-induced renal injury
remains uncertain.
Pathophysiology. The absence of tubular cell necrosis in
most patients with CsA-induced, reversible acute renal failure
casts doubt on whether CsA is, in fact, a tubular toxin as was
initially proposed [5, 141. Only when given to rodents in doses
that are an order of magnitude larger than those administered to
humans has significant morphologic evidence of tubular damage
been observed [14, 15], Such experimental tubular damage is
accompanied also by leakage into urine of lysosome-associated
enzymes, such a N-acetyl-p glucosaminidase (NAG) [14], a
phenomenon not observed in CsA-treated patients [16].
On the other hand, when rats are given acute intravenous
infusions or intraperitoneal injections of CsA daily for 7 days in
doses similar to those used therapeutically in humans, the
regimen produces a steep increase in renal vascular resistance
[16, 171. The consequent reduction in renal perfusion rate is
accompanied by a parallel reduction in glomerular filtration rate
(GFR), similar in magnitude to that observed during the revers-
ible, acute renal injury in humans [16]. The precise mechanism
by which CsA mediates renal vasoconstriction remains un-
known. Increased efferent sympathetic nervous traffic to the
kidney as well as circulating catecholamines have been impli-
cated, as has activation of the renin-angiotensin system [171.
Also, loss of a modulating effect on renal vasoconstriction by
vasodilator prostanoids might be important [18], as suggested
by the occurrence of unusually severe renal ischemia when
inhibitors of renal prostaglandin synthesis are administered
concurrently with CsA [17, 19]. That CsA might induce its acute
nephrotoxic effects via renal cortical vasospasm is suggested
further by its ability to augment hemodynamically mediated,
experimental renal injury, such as that following infusion of
endotoxin [20] or renal artery clamping for 60 minutes [21].
Current evidence from animal models tends to support the
concept that episodes of reversible, acute renal injury during
CsA therapy are a consequence of severe renal vasoconstric-
tion.
Protracted acute renal failure
Clinical features. Less frequent than the transient form of
renal injury, but by no means rare among CsA-treated patients,
is a severe form of acute renal failure (ARF) that is protracted
beyond one week. Protracted ARF has been reported most
frequently among recipients of cadaveric renal allografts. This
association might reflect simply the current preponderance of
this indication for CsA therapy. On the other hand, the disturb-
ingly high prevalence of protracted ARF among cadaveric renal
transplant recipients might reflect CsA's ability to potentiate
other acute ischemic renal injuries to which such grafts are
vulnerable. In two large, controlled multicenter studies, 13%
and 34%, respectively, of all CsA-treated recipients of cadav-
eric renal allografts had their treatment subsequently converted
to azathiopnne and prednisone during the first year of therapy
because of intractable azotcmia [22, 231. The large disparity in
the apparent prevalence of protracted, CsA-associated ARF
between these two studies was probably related to differences
in the condition of the kidney at the time of donation.
The role of preexisting ischemic damage to the donor kidney
is exemplified by a recent report of protracted ARF from the
Australian province of New South Wales where, in the absence
of brain death legislation, it is permissible to harvest a cadaveric
kidney for transplantation only after the heart has stopped
beating. Not surprisingly, the incidence of postischemic acute
tubular necrosis was very high, and more than 50% of such
grafts failed to function (so-called "primary non-function")
after transplantation [24]. Whereas the onset of renal allograft
function was observed after an average of 12 days among
patients receiving azathioprine and prednisone, the correspond-
ing delay in the onset of function was greatly prolonged—to
between 21 and 98 days—after transplantation among 37 of 51
recipients treated with CsA. Furthermore, in one-quarter of
CsA-treated patients with protracted ARF, renal function did
not resume until CsA therapy had been withdrawn altogether
and replaced by conventional immunosuppression. Thereafter,
a prompt recovery of renal function pointed strongly to CsA as
the cause of the prolonged renal injury. A similar prolongation
of acute renal failure complicating septicemia or surgery has
been observed in recipients of bone marrow and heart trans-
plants [7, 25]. When physicians have failed to withdraw CsA
under these circumstances, the protracted ARF has often been
irreversible.
Sometimes CsA therapy has to be discontinued because of
protracted ARF not only in cadaveric renal allografts exhibiting
primary non-function, but also in functional renal allografts. In
one large center, protracted ARF was observed in up to 10% of
functional grafts treated with CsA [26]. In many instances of
protracted ARF in functional renal allografts, no causative
factor other than CsA has been identified [26, 271. In other
transplants, one or more episodes of acute rejection hav
preceded the development of CsA-associated, protracted ARF
[26]. The latter circumstance might represent an example of an
adverse cumulative effect on the kidney of an unrelated isehe-
mic renal insult (in this case, acute rejection) and CsA therapy.
it is noteworthy that resolution of renal function in patients with
protracted ARF after CsA therapy has been withdrawn is
seldom complete. Irrespective of whether this severe renal
injury occurs in a cadaveric allograft that never functions or de
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novo in a functional graft, low-grade azotemia persists even
after CsA withdrawal [24, 26].
Histopathology. The morphologic changes observed in tubu-
lar cells of patients with transient ARF are even more pro-
nounced when azotemia has been prolonged for several weeks.
Giant mitochondria in cells of the proximal convoluted tubule
are more numerous, whereas cells of the straight segment of the
proximal tubule become increasingly vacuolated when azote-
mia is protracted. Prolonged acute renal injury appears also to
result in microcalcification within or adjacent to discrete tubular
cells [11]. Perhaps more diagnostic of CsA-induced protracted
renal injury than these tubular abnormalities is the development
of an arteriolopathy. Mihatsch and coworkers observed ultra-
structural evidence of protein deposition within the walls of
arterioles and small arteries of the renal cortex; light micros-
copy revealed arteriolar wall hyalinosis with luminal irregular-
ity and narrowing [111. Of interest is a more recent report by
Sommer et al of an irreversible form of protracted ARF in renal
allografts [27]. The most striking finding was an obliterative
arteriopathy involving interlobular and arcuate vessels. Serial
biopsies revealed first fibrin and platelet adherence to vascular
endothelium followed by progressive hyperplastic intimal thick-
ening with intraluminal narrowing. The morphology of circulat-
ing erythrocytes was indicative of microangiopathic hemolysis,
that is, the hemolytic-uremic syndrome. The arteriopathy in-
variably was accompanied by light microscopic evidence of
patchy tubular cell necrosis and glomerular ischemia. This
fulminant renal injury failed to resolve after withdrawal of CsA
therapy, and accounted for the loss of 7.5% of renal allografts in
the reporting institution. A milder form of arteriopathy that was
compatible with survival of a functional renal allograft was
observed also in biopsies of fully 20% of the remaining CsA-
treated patients in this series; this finding suggested a spectrum
of damage of varying severity to the vascular tree. Because of
the absence of tubulitis, glomerulitis, and interstitial infiltrates,
Sommer and associates proposed that CsA per se rather than
rejection was responsible for the devastating renal injury [27].
More widely recognized, and perhaps the pathologic hall-
mark of protracted ARF induced by CsA, is the development of
an exuberant, diffuse, interstitial fibrosis [11, 24, 28]. In con-
trast to the arteriopathy, which has been reported only in the
renal allograft, we have observed diffuse interstitial fibrosis in a
number of CsA-treated heart transplant recipients who have
come to autopsy with irreversible, protracted ARF. The same
also has been true of CsA-treated recipients of bone marrow
transplants who have died with protracted ARF [7]. Thus, this
alteration of the interstitial compartment is by no means unique
to the renal allograft and appears to be linked strongly to severe
CsA nephrotoxicity per se. That this is so is suggested by the
finding on renal biopsy specimens of diffuse interstitial fibrosis
in a majority of renal allograft recipients in whom recovery from
protracted ARF did not eventuate until CsA therapy was
withdrawn [11, 24, 28].
Pathophysiology. As I stated before, few animal studies have
examined the long-term effects of CsA on the kidney. The
ability of CsA to exacerbate acute renal injury following tran-
sient renal artery clamping [211 or infusion of endotoxin in the
rat [201 might be relevant to protracted ARF in CsA-treated
humans. As in humans, recovery from postischemic ARF in the
rat usually occurs in the second week after injury [29]. Recov-
ery is characterized by healing of tubular cell injury and is
heralded by a progressive increase in the rate of renal blood
flow [29—31]. It is possible that CsA's ability to increase renal
vascular resistance might prevent the increase in renal blood
flow that is necessary to promote resolution of concurrent,
postischemic renal injury in allografts exhibiting primary non-
function. The demonstration that CsA administration exacer-
bates intravascular thrombus formation in rabbits either with
serum sickness [32] or the Schwartzman reaction [20] adds
weight to the notion that CsA acts synergistically with unrelated
vascular injuries to cause protracted renal damage [21, 331. In
addition to its proclivity for inducing renovascular damage,
CsA also might be a stimulus to interstitial cell proliferation.
Jackson and Humes reported an increase of thymidine incor-
poration into the renal cortex, which is confined to cells of the
interstitium in rats receiving CsA [34]. These proliferating cells
might prove to be fibroblasts, or might lead indirectly to the
diffuse interstitial fibrosis that has been so prevalent after
intractable episodes of protracted, CsA-associated ARF.
Chronic nephropathy
Clinical features. Numerous reports of recovery from pro-
tracted ARF generally have been reported by their authors to
indicate complete reversal of this severe, CsA-associated renal
injury. Because these reports are replete with examples of
sustained or progressive azotemia long after CsA has been
withdrawn, we must surmise that recovery is at best partial [24,
26, 35—37]. An acute injury that becomes protracted probably
evolves into a chronic form of renal injury under these circum-
stances. Equally misleading is the frequently quoted inference
that the absence of acute or protracted CsA-associated
nephrotoxicity is synonymous with normal renal function in
patients receiving long-term CsA therapy. Six randomized,
controlled trials have appeared from single or multiple centers
comparing CsA with other agents as immunosuppressants after
renal transplantation [22, 23, 38—411. When the results of all six
trials are combined, the one-year cadaveric graft survival rate
was 79% in CsA-treated recipients, compared with only 65% in
recipients treated with other agents (P < 0.01). Paradoxically,
in these same trials, chronic CsA therapy was associated at one
year with a significant and sustained increase in serum creati-
nine concentration to 2.0 mgldl, a finding not observed in
non-CsA-treated patients. In view of the reduced incidence and
severity of rejection, the persistent azotemia strongly suggests
that CsA causes a chronic, intrinsic renal injury.
Any attempt to define the nature and extent of CsA-associ-
ated chronic nephropathy in renal transplants is hampered by
the contribution of concomitant, chronic rejection. No such
difficulties are encountered, however, in cardiac transplant
recipients, who have healthy native kidneys, and who have also
experienced an increase in one- and two-year cardiac graft
survival over that achieved earlier with azathioprine-based
immunosuppression [25, 42]. Figure 2 (upper panel) compares
the prevailing level of serum creatinine concentration among
CsA-treated, one-year survivors of heart transplantation at
Stanford University with that of a historic control group that
had been treated with azathioprine. The serum creatinine
concentration was below 1.4 mg/dl in the vast majority of
azathioprine-treated recipients. In contrast, serum creatinine
concentration exceeded 1.4 mg!dl in almost all patients receiv-
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Fig. 2. Upper histogram. Prevailing serum creatinine levels 12 months
after heart transplantation in all surviving patients treated with pred-
nisone and either cyclosporine (hatched bars) or azathioprine (open
bars). Lower histogram. Corresponding distribution qf rates qfglomer-
ular filtration (inulin clearance) in approximately one-third of each qf
the two treatment groups represented in the upper panel.
ing CsA for 12 months. The mean serum creatinine concentra-
tion of 2.1 mgldl in the CsA-treated patients significantly
exceeded the corresponding value of 1.2 mg/dl in the azathio-
prine-treated group (P < 0.001). Approximately one-third of the
members of each treatment group were selected at random for
detailed physiologic studies to elucidate the CsA-associated
chronic azotemia. As can readily be seen in the lower histogram
in Figure 2, the inulin clearance was in the normal range (above
80 mllmin!1.73 m2) in a clear majority of the azathioprine-
treated group, but was subnormal with only one exception in
the CsA-treated group. As with serum creatinine levels, there
was little overlap between the two populations (Fig. 2). Mean
GFR in the CsA-treated group was depressed by almost 50%, 53
4 versus 91 4 mI/mm/I .73 m2 in the azathioprine group (P
<0.001). An evaluation of the determinants of OFR in the two
groups of heart transplant recipients illustrated in the lower
panel of Figure 2 suggests that the glomerular hypofiltration
associated with chronic CsA therapy was due in large part to a
reduction of renal plasma flow combined with a depressed
glomerular ultrafiltration coefficient [42, 43]. Neither of the
latter findings in the CsA-treated group could he attributed to
impaired performance of the cardiac allograft.
Other features of the chronic nephropathy in CsA-treated
heart transplant recipients included severe arterial hyperten-
sion, mild proteinuria, and tubular dysfunction. That this
chronic renal injury is likely irreversible was suggested by a
constellation of histopathologic findings indicative of a reduced
population of functioning nephrons in the kidneys of patients
treated with CsA for 12 months [42, 43].
The chronic renal injury attributed by the Stanford study to
CsA is not unique to cardiac transplant recipients. This conclu-
sion is evidenced by determinations of the GFR in patients
receiving CsA chronically for indications other than cardiac
transplantation. Thus the mean inulin clearance in 9 liver
transplant recipients was reduced to 50% below pretranspiant
levels after 12 months of CsA therapy, 46 versus 98 ml/min/l.73
m2, respectively [44]. Similarly, the GFR (estimated by the
clearance of 99"1-Tc-DTPA) was severely depressed in 14
CsA-treated recipients of long-surviving renal transplants who
exhibited stable function and no evidence of rejection 1451.
Although no control determinations were given in the latter
study, the reported value for mean GFR of only 43 mI/mm/I .73
m2 is only about one-half of what might be expected of an
uninjured renal allograft under these circumstances. Taken
together, these observations suggest that substantial chronic
renal injury, with depression of GFR by about 50% on average,
is common to all allograft recipients treated with CsA for
approximately 12 months. Longitudinal study of the Stanford
heart transplant recipients suggests, moreover, that CsA-asso-
ciated chronic nephropathy is progressive [46]. Reexamination
after an additional 12 months of 17 members of the CsA group
illustrated in Figure 2 (lower panel) revealed a further signifi-
cant reduction of GFR by 18%, To date, 3 of 67 cardiac
transplant recipients at Stanford receiving CsA for 2 years or
longer have developed end-stage renal failure [43]. Yet another
CsA-treated heart transplant recipient at the University of
Pittsburgh has required renal transplantation for end-stage renal
failure [25].
Although CsA-associated nephropathy has not been identi-
fied as a cause of graft loss among renal transplant recipients, it
seems likely that this possibility has been overlooked. A
controlled multicenter trial in Europe reported a rate of graft
loss after 3 years in those randomized to CsA of 34%, and a
mean serum ereatinine concentration of 2.4 mg/dl, in 3-year
survivors with functional grafts (versus 1 .7 mgldl in the control
azathioprine-treated grafts that continue to function after 3
years) [471. Incremental graft loss and persisting azotemia in
those with surviving grafts is true also at 2-year followup in the
Canadian multicenter study [48]. In yet another report by
Merion and coworkers, 23 cadaveric renal transplant recipients
received CsA continuously for 3 years or more, and the mean
serum creatinine level among these patients was 2.6 mg/dl [49).
These high serum creatinine values in patients with long-
surviving, CsA-treated renal allografts attest to an even more
substantial GFR reduction than that reported in cardiac trans-
plant recipients at one year, and point to a severe, chronic renal
injury. I believe that it is conceivable that late graft loss (after
one year) in these centers could he due, at least in part, to a
progressive, CsA-associated chronic nephropathy, and not ex-
clusively to chronic rejection as concluded by the authors of
these reports.
Ilistopathology. Only limited histopathologic information is
available on the pathologic correlates of CsA-associatcd chron-
ic nephropathy. The changes among long-surviving Stanford
cardiac transplant recipients appear to represent a more ad-
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vanced stage than do those described by Mihatsch et al in renal
transplant recipients with protracted, acute injury [11]. Most
striking has been a patchy injury of variable severity to the
tubulointerstitial compartment. Tubules in affected zones of the
renal cortex exhibit severe atrophy with thickening of their
basement membranes, and interstitial fibrosis is prominent. In
addition, a focal and segmental sclerosis of glomeruli has been
observed [42, 43]. Focal hyalinosis of small arteries and arteri-
oles is invariable in biopsies and autopsies of chronically
CsA-treated cardiac transplant recipients. A consequent ische-
mia of the zone of renal cortex supplied by such compromised
vessels possibly could account for the tubulointerstitial changes
and glomerular sclerosis. Persistent hypertension also might
aggravate the progressive destruction of nephrons. A chronic
lesion of the tubulointerstitial compartment similar to that in
cardiac transplant recipients has been described also in renal
transplant recipients treated with CsA for I to 4 years [50].
Although significantly less prevalent, similar morphologic
changes were observed also in long-surviving renal transplant
recipients treated with azathioprine [50]. Such changes among
the latter recipients presumably are a consequence of previous
rejection episodes and emphasize the difficulty of distinguishing
clearly the changes of CsA-associated chronic nephropathy
from those due to chronic renal allograft rejection. In the
absence of specific clinical or histopathologic characteristics to
differentiate these two entities, the attribution of late graft loss
in ongoing trials to chronic rejection rather than to chronic
CsA-induced renal injury requires careful reappraisal.
Pathophysiology. In the absence of an experimental animal
model, the precise pathogenesis of CsA-associated chronic
nephropathy in humans must remain speculative. The numer-
ous observations I have mentioned can be reconciled, however,
with the hypothetical pathogenetic sequence illustrated in Fig-
ure 3. According to this scheme, administration of CsA in a
"nontoxic" dosage is associated from the outset with persistent
renal vasoconstriction [16, 17]. The ensuing reduction in renal
plasma flow is accompanied by a parallel fall in GFR sufficient
to explain the modest azotemia that has been widely observed
after several weeks of therapy with this agent [42, 43, 51].
Episodes of CsA-associated, transient, acute renal failure then
can be viewed as no more than dose-dependent falls in renal
blood flow below an already reduced baseline value (Fig. 3).
Renal dysfunction early in the course of CsA therapy appears
to be a consequence of reversible vasoconstriction. This finding
is suggested by a return of serum creatinine levels from an
elevated to a normal range when the agent is withdrawn within
approximately 6 months [19, 35, 52]. More direct evidence that
reversible renal vasoconstriction may be invariable during the
early months of CsA therapy recently has been provided by
Curtis and associates [53]. They withdrew CsA therapy solely
to reduce the financial burden in 14 recipients with stable renal
allografts. Substitution of azathioprine for the CsA resulted in a
significant increase (36%) in renal plasma flow (from 236 60 to
320 80 mllmin, P < .001). In contrast, the serum creatinine
concentration remained unchanged, emphasizing the limited
ability of this laboratory test to detect large CsA-related in-
creases in renal vascular resistance.
Although these observations suggest a return to normal rates
of glomerular perfusion and filtration when the duration of CsA
therapy is 6 months or less, the outcome is less favorable when
Months on cyclosporine
Fig. 3. Hypothetical course of a chronic renal injury associated with
CsA treatment. Rates of renal blood flow and glomerular filtration
(lower panel) are reversibly reduced by about 40% for approximately 6
months. The early part of the course may be punctuated by reversible
episodes of acute renal insufficiency (arrows). After 12 months there
follows a further progressive decline in glomerular filtration rate (GFR)
that is disproportionate to the corresponding fall in renal blood flow
(RBF), and which appears to be irreversible. Arterial hypertension
(upper panel) appears early in the course of the injury and may
contribute to the late deterioration in glomerular function.
treatment is administered continuously for 12 months or longer.
Under these conditions a progressive, albeit slow, decline of
GFR appears to indicate the development of an irreversible
renal injury [43, 46]. As Figure 3 illustrates, the substantial, late
reduction of GFR is accompanied by a low filtration fraction,
implicating factors besides reduced renal plasma flow [42]. A
constellation of histopathologic findings points to a reduction in
the number of functional nephrons with an attendant loss of
glomerular filtration surface area at this time [42, 43, 50].
The model of CsA-associated chronic nephropathy proposed
in Figure 3 also emphasizes the invariable coexistence of
arterial hypertension (upper panel) [43, 54]. Although it remains
to be determined whether such hypertension is secondary to the
chronic renal injury or due to some primary effect of CsA on the
systemic vasculature, the elevation in arterial pressure is not
associated with increased plasma renin activity. To the con-
trary, the renin-angiotensin-aldosterone axis appears to be
depressed in patients receiving long-term CsA therapy [43,
54—56]. Regardless of its precise pathogenesis, coexistent arte-
rial hypertension might be important in facilitating the renal
arteriolar damage and focal and segmental glomerulosclerosis
that have been described in patients with CsA-associated
chronic nephropathy [57—60].
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It is too early to determine whether this chronic renal injury
is irrevocably progressive. At least in some cardiac transplant
recipients, progressive renal failure does occur [461, and several
instances of patients developing end-stage renal failure have
been reported [25, 43]. The patient presented today exemplifies
well a CsA-associated chronic nephropathy that appears to be
progressing toward end-stage renal failure.
Because it can take a decade or more for a chronic renal
injury to produce end-stage renal failure, it might be that the
isolated examples I have used represent merely the vanguard of
patients with CsA-associated chronic nephropathy who are
destined to progress irrevocably but more slowly to end-stage
renal failure. It has been argued, on the basis of a stable level of
chronic azotemia after 2 to 5 years of therapy, that chronic
ncphropathy does not progress in CsA-treated renal transplant
recipients [49, 51]. This argument is based on group rather than
individual data, however, and fails to take into account the
increase in tubular creatinine secretion that commonly is ob-
served during the course of chronic glomerular injuries, includ-
ing that induced by CsA [61, 621. An incremental rise in tubular
creatinine secretion could blunt a reciprocal increase in serum
creatinine concentration when GFR declines at a modest pace,
and this alteration could lead one to the erroneous impression
that the glomerular injury of CsA-associated chronic nephrop-
athy is non-progressive, when in reality the GFR is declining
slowly. Given these considerations, it is not implausible that
CsA-associated chronic nephropathy will contribute to the late
loss of at least some renal allografts. if this prediction proves
correct, the climbing rates of I- and 2-year renal allograft
survival that have been achieved with this agent to date could
be reversed with the passage of time.
Conclusions and recommendations
Theevidence I have summarized today indicates that CsA, as
it has been used in the first part of this decade, can lead to
acute, subacute, or chronic renal damage. A number of new
approaches have been adopted in the past 2 years that are
designed to minimize nephrotoxicity while retaining the supe-
rior immunosuppressive effects of this powerful agent. For
example, initiation of CsA therapy is often delayed until after
the onset of adequate renal function in cadaveric renal allografts
to avoid potentiating the postischemic injury to which such
grafts are vulnerable. Another approach has been to withdraw
CsA after 3 to 6 months of therapy [35, 63, 64]. This time
interval coincides with the reversible phase of CsA-associated
renal injury (Fig. 3), while covering that period during which the
allograft is most susceptible to acute rejection. Unfortunately,
the substitution of azathioprine for CsA in graft recipients has
been followed frequently by an episode of acute rejection [35,
63, 64]. An alternative approach has been the combination of
low-dose CsA with azathioprine and prednisone in so-called
"triple therapy" [651. As Figure 4 shows, serum creatinine
levels have been lower at all times after transplantation in
cardiac transplant recipients treated with this regimen. Never-
theless, mean serum creatinine concentration has continued to
rise progressively into an abnormal range, albeit more slowly.
This observation suggests that low-dose, long-term therapy has
attenuated CsA-associated chronic nephropathy into a milder
form rather than eliminated it.
Although we have hardly begun to discover a safer approach
to the use of CsA in aliograft recipients, we are nevertheless
witness to a proliferation of the use of this agent for conditions
other than organ transplants [6, 19, 52, 66—68]. In light of its
potential for causing extensive renal damage, this expanded use
of CsA for a variety of diseases characterized by immune
inflammation is difficult to justify, The dilemma posed by this
development is well illustrated when one considers the natural
history of diseases such as type-I diabetes mellitus, systemic
lupus erythematosus, and minimal-change nephropathy, in
which CsA therapy has been employed to prevent the develop-
ment of severe glomerulopathy. End-stage renal failure is likely
in only a minority of patients with systemic lupus erythemato-
sus [691, in an even smaller percentage of those with minimal-
change nephropathy 170], and only after a decade or more of
type-I diabetes [71]. Based on our present knowledge, it is not
certain that CsA-induced injury will not devastate the kidney
even more rapidly and commonly than would these diseases.
In conclusion, I propose that a strong case can be made for
limiting the use of CsA to the field of organ transplantation until
measures can be developed that further widen the margin of
safety between its immunosuppressive and nephrotoxic effects.
In addition to exploring modified dosage regimens, we should
(1) adopt sensitive techniques to supplement creatinine-based
monitoring in the detection of significant renal dysfunction, and
(2) use more liberally the renal biopsy late in the course of CsA
therapy to identify in a timely fashion irreversible lesions that
can be expected to impair renal function progressively.
Questions and answers
DR. DENNIS SLOAN (Attending Nephrolo gist, Michael Reese
hospital, Chicago, Illinois): In view of the similarity between
the renal lesion of focal segmental sclerosis and that of CsA
nephrotoxicity, I was wondering whether patients treated with
CsA are also proteinuric. if so, might the course of their renal
disease be changed by altering the degree of proteinuria?
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DR. MYERS: The chronic form of injury is associated with
proteinuria of modest proportions, usually less than 1 g124
hours. It does not in this respect resemble the idiopathic form of
focal and segmental glomerulosclerosis, which usually causes
nephrotic-range proteinuria. It is more analogous to the focal
sclerosing glomerulopathies that complicate obstructive ne-
phropathy and renal agenesis, and that are accompanied only
terminally by heavy proteinuria.
DR. SERAFINO GARELLA (Department of Medicine, Michael
Reese Hospital): Could you comment on the pharmacokinetics
of cyclosporine A? Specifically, are there data on whether
toxicity and/or pharmacologic effects might be related to tissue
levels rather than to blood levels? Does a change in GFR by
itself require a modification in the dose of cyclosporine A?
DR. MYERS: CsA is very lipophilic and binds avidly to cell
membranes. Because of binding to erythrocyte membranes, its
concentration in whole blood is higher than that in serum, and
many recommend the former fluid for monitoring toxicity. A
more direct approach has been reported by von Willebrand and
Hayry [5]. They have shown a correlation between acute
nephrotoxicity and the binding of CsA to tubular cell mem-
branes in needle aspirates of the renal cortex. As yet, we do not
have a way of monitoring the toxicity of CsA that is both
sensitive and convenient.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital): What is known about the dose-
response curve with respect to the immunosuppressive effects
of CsA? Do we have good evidence that the doses currently
regarded as therapeutically efficacious are in fact as low as they
could be?
DR. MYERS: Early studies suggested that a trough serum level
of CsA above 200 ng/ml was necessary to achieve immunosup-
pression. Because of nephrotoxicity, however, the targeted
trough levels are currently much lower, usually below 150
nglml. Whether there is a loss of immunosuppressive efficacy at
the lower levels is hard to judge because the lower dosage
schedules employed currently are often combined with azathi-
oprine and invariably with prednisone.
DR. JOHN T. HARRINGTON (Chief, Department of Medicine,
Newton- Wellesley Hospital, Newton, Massachusetts): You
noted that renal vascular resistance was increased acutely by
the intravenous administration of cyclosporine. Can the vaso-
constriction be blocked by the concomitant administration of a
vasodilator such as acetylcholine?
DR. MYERS: Ferris and coworkers have shown that vasodila-
tory prostaglandins modulate the vasoconstrictor effects of
intravenously administered CsA in the rat [17]. In view of the
need to give CsA chronically to graft recipients, however, I
doubt whether concomitant vasodilator therapy would be prac-
ticable.
DR. COHEN: Your hypothesis about the pathogenesis of the
renal lesion caused by CsA appears to me to contain a contra-
diction. How can hemodynamically mediated glomerulosciero-
sis play a critical role in the progression of CsA-induced renal
failure if the drug is a renal vasoconstrictor? Wouldn't the
vasoconstricting effect protect the glomerular capillaries from
hyperfiltration and hemodynamic injury?
DR. MYERS: To achieve simultaneous underperfusion and
hypertension of glomerular capillaries, it would be necessary
for CsA to exert a disproportionate constrictor effect on efferent
arterioles. Such a selective effect is observed with many
vasoconstrictor substances, and is not implausable in the case
of CsA.
DR. BENJAMIN SPARGO (Department of Pathology, Univer-
sity of Chicago, Chicago): Do you have detailed observations
on the preglomerular arterioles in your biopsy material? In
patients with focal segmental sclerosis and in those with idio-
pathic nephrotic syndrome, we have found a high incidence of
vascular lesions that were not related to hypertension. Have
you found anything similar to this? Second, in our cases of
presumed cyclosporine toxicity, we find a loss of glomerular
vascularity and a decrease in glomerular size. As a result, the
mesangium is relatively more prominent. I wonder whether you
have seen this.
DR. MYERS: Indeed, hyalinosis of arterioles and small arter-
ies is a hallmark of the pathology of CsA nephrotoxicity. It has
been a prominent finding in our cases of chronic nephropathy.
I am not sure that it can be dissociated from hypertensive
injury, however. I agree that ischemic "collapsed" glomeruli
are quite common, even with the chronic injury. However, the
average surface area of glomerular profiles in this disorder is not
reduced in our experience, so that the fractional increase in
mesangial area that we have described presumably reflects
mesangial expansion.
DR. FREDRIC COE (Renal Section, Mitchell Hospital, Chi-
cago): Bryan, in trying to understand what the drug is doing, I
am struck by the fact that you can't get a reliable toxicity model
in any experimental animal so far. Also it is striking that the
liver, which processes this drug, is not dramatically affected,
whereas the kidney, which handles the drug hardly at all, is
extraordinarily affected. Is it certain that the drug is a primary
nephrotoxin? Perhaps it has some general effect, on endothelial
cells for example, that is expressed more dramatically in the
kidney but that isn't specific to the kidney.
DR. MYERS: I think that is entirely possible. I alluded earlier
to studies of isolated, rabbit aortic strips in which an inability of
endothelial cells to synthesize prostacyclin has been docu-
mented. The high prevalence of arterial hypertension early in
the course of therapy with CsA is also consistent with the
drug's ability to increase resistance in the systemic vasculature.
The weight of evidence suggests, however, that the renal
vascular bed is particularly vulnerable to CsA, and I suspect
that microvascular injury in the kidney forms the basis of CsA
nephrotoxicity.
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital):
What research is currently being done to alter the cyclosporine
molecule, or to develop an alternative drug that retains the
favorable immunosuppressive properties but is less nephro-
toxic?
DR. MYERS: Cyclosporine G is a modified form of CsA that is
currently under investigation with precisely the objectives that
you have outlined.
DR. GARY TOBACK (Renal Section, Mitchell Hospital): I have
two questions. First, what are the mechanisms that underlie
increased tubular secretion of creatinine in renal failure in
general, and in response to cyclosporine A administration in
particular? Second, is there any evidence that the renin-angi-
otensin mechanism is activated in patients with CsA nephro-
toxicity? The renal hypoperfusion that you describe should
activate that system.
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DR. MYERS: The fractional secretion of creatinine is related
inversely to GFR in patients with chronic glomerular diseases.
I suspect that this represents a form of tubuloglomerular
balance and is fundamentally an adaptive mechanism to elimi-
nate creatinine. The phenomenon is entirely nonspecific and by
no means unique to chronic CsA nephropathy. Ferris and
colleagues showed that the renin-angiotensin system is acutely
activated when CsA is infused into rats [17]. In contrast, the
system appears to be suppressed in humans receiving CsA over
long periods.
DR. SHELDON HIRSCH (Renal Fellow, University of Chi-
cago): The reduction in ultrafiltration coefficient following CsA
would appear to explain the change in the dextran sieving curve
that you observed. If that is true, how can you argue that the
dextran sieving curve is evidence for intracapillary hyperten-
sion?
DR. MYERS: You correctly point out that both a selective
reduction of Kf and a selective increase in transmembrane
hydraulic pressure (AP) would lower the sieving coefficient of a
given dextran. We cannot distinguish between those two pos-
sibilities. We used the dextran sieving curve to argue that the
lower GFR in chronic CsA nephropathy could not be caused by
lowering of AP. This perturbation would elevate the dextran
sieving coefficients and not lower them as we observed.
DR. GARELLA: Is is possible that the chronic renal injury that
you have described might be due not to a direct nephrotoxic
effect of cyclosporine A, but to its effectiveness as an im-
munosuppressive agent? In AIDS, which is characterized by
profound defects in cellular immunity, a renal lesion has been
reported that in many ways appears similar to that which you
described as manifest in the chronic type of cyclosporine A
nephropathy. If this renal lesion were secondary to the im-
munosuppression resulting from the long-term administration of
cyclosporine A, chronic nephropathy would be a side effect
linked to the therapeutic mode of action of the drug. If so,
modification of the molecular structure of cyclosporine A would
be unlikely to prevent this side effect, unless such modifications
were coupled with a marked weakening of its therapeutic
effectiveness.
DR. MYERS: An unusually high prevalence of focal glomeru-
lar sclerosis has been associated with AIDS. Recently this has
been found to be true only of AIDS sufferers who are also
intravenous morphine abusers [72]. I think it unlikely, there-
fore, that the nephropathy of CsA represents a response to
immunodeficiency.
DR. KAJ LAU (Renal Division, Michael Reese Hospital):
What is the mechanism for the generalized vasoconstriction and
the hypertension induced by CsA? Is it possible that the chronic
renal insufficiency is a function of unopposed hypertension?
Can rigorous control of the hypertension attentuate or abolish
the chronic renal injury?
DR. MYERS: That is a difficult question to answer. Cause and
effect are difficult to sort out. We have, in fact, rigorously
controlled the hypertension in our CsA-treated heart transplant
recipients, in part to unload the grafted heart. Such treatment
has not prevented the chronic renal injury that I have described.
It does not follow, however, that while controlling arterial
hypertension we are also correcting glomerular capillary hyper-
tension. Possibly, agents with this latter specific effect might
avert renal injury.
DR. LAU: Are there good data evaluating various tubular
functions in patients with cyclosporine nephrotoxicity?
DR. MYERS: In the human, PAR extraction is reduced. In
acute animal studies, lysozomal enzymes have been liberated in
excessive amounts from proximal tubular cells. Whether prox-
imal tubular dysfunction is due to a primary tubulotoxic effect
of CsA or is secondary to renal ischemic damage remains to be
determined.
DR. COHEN: In view of your concern about nephrotoxicity
from CsA, what are your current recommendations for the
management of renal allograft recipients in whom the risk of
rejection is, of course, still a major problem?
DR. MYERS: If, as I have suggested, the initial vasospasm
associated with CsA therapy remains reversible for several
months, it would be ideal to use CsA only during this interval.
This coincides also with the highest likelihood of acute rejection
episodes. Unfortunately, it has been dillIcult in practice to
withdraw CsA after, say, 6 months, because of a predisposition
to subsequent rejection. Nevertheless, this approach combined
with low dose schedules and "triple therapy" looks to be the
most promising.
DR. HARRJNGTON: Is that time interval 4, 5, 6 months, or
more? What is your best estimate?
DR. MYERS: Luke et a! demonstrated a large increase in renal
plasma flow when CsA was withdrawn as long as 8 or 9 months
after transplantation. Our own observations suggest irrevers-
ibility beyond 12 months of CsA therapy. If pressed, I would
say that CsA should be withdrawn after 6 months.
Reprint requests to Dr. B. Myers, Division of Nephrology, S215,
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